Persevering with ProstVac

After more than 20 years in clinical development, including over six years in the hands of Bavarian Nordic A/S, ProstVac rilimogene galvacirepvec found a potential commercial partner in Bristol-Myers Squibb Co.

Whether BMS exercises its option, and how much of the potential $975 million in deal value Bavarian Nordic gets, depends on how much of a survival benefit the prostate cancer vaccine can show in Phase III testing. But the real upside could lie in combining ProstVac with the pharma's pipeline of checkpoint inhibitors...